ARTICLE | Company News
Critical Outcome Technologies, Portage Biotech deal
March 3, 2014 8:00 AM UTC
The companies signed a non-binding letter of intent to form a JV to develop Critical Outcome's preclinical cancer compound COTI-2. The JV would have an exclusive license to develop COTI-2 from the st...